Up next

Company Executives Outline Growth Strategies and Expansions at the DCAT Member Company Announcement Forum

In this special issue of DCAT Value Chain Insights, we are providing information that would have been presented at the DCAT Member Company Announcement Forum at DCAT Week ’20. Originally scheduled to be held on March 23 in New York, these announcements were selected by the Announcement Oversight Task Force, as they present the latest major company news impacting the pharmaceutical manufacturing value chain. CEOs and senior executives from DCAT member companies outline their companies’ growth strategies by providing updates on key mergers and acquisitions and expansions with news from the following companies: Cambrex, Recipharm, Thermo Fisher Scientific, Lonza, SK pharmteco, Catalent, Biocon, CordenPharma, and WuXi STA. The individual news developments are outlined below.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

CDMOs/CMOs: The Key Moves in 2026

By
What have been the key moves—capacity additions and acquisitions by CDMOs thus far in 2026 and what may be on the horizon?

What’s Trending in Excipients

By
Excipients play a crucial role in formulation development, but what barriers to innovation in excipients exist and how is the industry addressing?

Pharma M&A: The Deals & the Molecules

By
What have been the key mergers and acquisitions by the large and mid-sized pharma companies thus far in 2026? DCAT Value Chain Insights evaluates the deal-making and the molecules involved. 

Manufacturing Strategies: AstraZeneca

By
AstraZeneca’s strategy to increase its revenues in the US is accompanied by select investments in China on an R&D and manufacturing basis, with the latest, plans for a biomanufacturing JV.